

## PerCP anti-mouse CD45 Antibody

<b>Catalog# / Size</b>	103129 / 25 µg 103130 / 100 µg
<b>Clone</b>	30-F11
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	T200, Ly-5, LCA
<b>Isotype</b>	Rat IgG2b, κ
<b>Description</b>	CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

### Product Details

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	Mouse thymus or spleen
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with PerCP under optimal conditions.
<b>Concentration</b>	0.2 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 <sup>6</sup> cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.  * PerCP has a maximum absorption of 482 nm and a maximum emission of 675 nm.
<b>Excitation Laser</b>	Blue Laser (488 nm)
<b>Application Notes</b>	Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.  Additional reported applications (for relevant formats) include: immunoprecipitation <sup>3</sup> , complement-dependent cytotoxicity <sup>1,5</sup> , immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections) <sup>4,6</sup> , Western blotting <sup>7</sup> , and spatial biology (IBEX) <sup>10,11</sup> . The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).

### Application References

1. Podd BS, *et al.* 2006. *J. Immunol.* 176:6532. (FC, CMCD) [PubMed](#)
2. Haynes NM, *et al.* 2007. *J. Immunol.* 179:5099. (FC)
3. Ledbetter JA, *et al.* 1979. *Immunol. Rev.* 47:63. (IP)
4. Simon DI, *et al.* 2000. *J. Clin. Invest.* 105:293. (IHC)
5. Seaman WE. 1983. *J. Immunol.* 130:1713. (CMCD)
6. Cornet A, *et al.* 2001. *P. Natl. Acad. Sci. USA* 98:13306. (IHC)
7. Tsuboi S and Fukuda M. 1998. *J. Biol. Chem.* 273:30680. (WB) [PubMed](#)

8. Liu F, *et al.* 2012. *Blood*. 119:3295. [PubMed](#)
9. Pelletier AN, *et al.* 2012. *J. Immunol.* 188:5561. [PubMed](#)
10. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A*. 117:33455-65. (SB) [PubMed](#)
11. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

## Product Citations

1. Quispe Calla N, *et al.* 2016. *Sci Rep.* 6:37723. [PubMed](#)
2. Filipello F *et al.* 2018. *Immunity.* 48(5):979-991. [PubMed](#)
3. Haratani K, *et al.* 2019. *J Clin Invest.* 130:374. [PubMed](#)
4. Garo LP, *et al.* 2021. *Nat Commun.* 12:2419. [PubMed](#)
5. Schädlich IS, *et al.* 2022. *iScience.* 25:104470. [PubMed](#)
6. Bruggemann TR, *et al.* 2022. *iScience.* 25:105185. [PubMed](#)
7. Sun J, *et al.* 2020. *Acta Biomater.* 289:106. [PubMed](#)
8. Shin J, *et al.* 2016. *Sci Rep.* 6:23426. [PubMed](#)
9. Bo Yu *et al.* 2018. *Cell stem cell.* 23(2):193-209. [PubMed](#)
10. Keeter WC, *et al.* 2022. *Eur Heart J Open.* 2:oeac028. [PubMed](#)
11. Di Martile M, *et al.* 2020. *J Immunother Cancer.* 8:. [PubMed](#)
12. Zhou J, *et al.* 2021. *Int J Med Sci.* 18:3516. [PubMed](#)
13. Lopez-Guadamillas E, *et al.* 2016. *Sci Rep.* 6:34542. [PubMed](#)
14. Kawashima N, *et al.* 2022. *Nat Commun.* 13:1624. [PubMed](#)
15. Lin H, *et al.* 2020. *Front Microbiol.* 1.330555556. [PubMed](#)
16. Stolp B, *et al.* 2022. *Cell Rep.* 38:110387. [PubMed](#)
17. Tilstam PV, *et al.* 2021. *J Clin Invest.* 131:. [PubMed](#)
18. Tajfirouz D, *et al.* 2017. *Virology.* 10.1016/j.virol.2017.02.022. [PubMed](#)
19. Go DM, *et al.* 2021. *Cell Mol Gastroenterol Hepatol.* 12:715. [PubMed](#)
20. Enriquez AB, *et al.* 2022. *iScience.* 25:104305. [PubMed](#)
21. Zhou HF, *et al.* 2022. *Front Pharmacol.* 13:778755. [PubMed](#)
22. Glaubitz J, *et al.* 2022. *Nat Commun.* 13:4502. [PubMed](#)
23. Royzman D, *et al.* 2022. *Front Immunol.* 13:1012647. [PubMed](#)
24. Ayasoufi K, *et al.* 2020. *Brain.* 3629:143. [PubMed](#)
25. Peng L, *et al.* 2020. *Transl Lung Cancer Res.* 0.892361111. [PubMed](#)
26. Liu YJ, *et al.* 2020. *Theranostics.* 10:5225. [PubMed](#)
27. Nguyen CM, *et al.* 2019. *Diabetes.* 68:1499. [PubMed](#)
28. Zhang C, *et al.* 2021. *Clin Transl Immunology.* 10:e1310. [PubMed](#)
29. She L, *et al.* 2021. *JCI Insight.* 6:e143509. [PubMed](#)
30. Lee M, *et al.* 2014. *PLoS One.* 9:112666. [PubMed](#)
31. Gabbita S, *et al.* 2015. *PLoS One.* 10: e0137305. [PubMed](#)
32. Enriquez AB, *et al.* 2022. *iScience.* 25:104305. [PubMed](#)
33. Law HL, *et al.* 2020. *Front Pharmacol.* 11:274. [PubMed](#)
34. Sears SM, *et al.* 2020. *Am J Physiol Renal Physiol.* 319:F674. [PubMed](#)
35. Taube C, *et al.* 2011. *PLoS One.* 6:e21799. [PubMed](#)
36. Yang S, *et al.* 2019. *Nat Commun.* 10:2782. [PubMed](#)
37. Fatkhullina AR *et al.* 2018. *Immunity.* 49(5):943-957. [PubMed](#)
38. Ngamsri KC, *et al.* 2021. *Int J Mol Sci.* 22:. [PubMed](#)
39. Amo-Aparicio J, *et al.* 2021. *Theranostics.* 11:9805. [PubMed](#)
40. Saitoh BY, *et al.* 2021. *Brain Behav Immun.* 95:362. [PubMed](#)
41. Aebischer D, *et al.* 2014. *PLoS One.* 9:99297. [PubMed](#)
42. Everard A, *et al.* 2014. *Nat Commun.* 5:5648. [PubMed](#)
43. Hrdinka M, *et al.* 2016. *PLoS One.* 11: 0162863. [PubMed](#)
44. Demandt JAF, *et al.* 2021. *Frontiers in Cell and Developmental Biology.* 9:664258. [PubMed](#)
45. He Y, *et al.* 2021. *Cell Metabolism.* 33(5):988-1000.e7. [PubMed](#)
46. Kumaran Satyanarayanan S, *et al.* 2019. *Nat Commun.* 10:3471. [PubMed](#)
47. Zou J, *et al.* 2021. *Cell Mol Gastroenterol Hepatol.* 12:983. [PubMed](#)
48. Mulas F, *et al.* 2020. *Cell Mol Immunol.* . [PubMed](#)
49. Mulder K, *et al.* 2021. *Immunity.* 54(8):1883-1900.e5. [PubMed](#)
50. Osaka M, *et al.* 2016. *Sci Rep.* 6:21391. [PubMed](#)
51. Davis M, *et al.* 2015. *J Immunol.* 194:2219. [PubMed](#)
52. West D, *et al.* 2014. *J Immunol.* 192:1762. [PubMed](#)
53. Wang F, *et al.* 2019. *Cell Death Dis.* 1.036111111. [PubMed](#)
54. Dmitrieva-Posocco O *et al.* 2019. *Immunity.* 50(1):166-180. [PubMed](#)
55. Arcangeli S, *et al.* 2022. *J Clin Invest.* 132:. [PubMed](#)
56. Wang X, *et al.* 2018. *Cell Death Dis.* 9:578. [PubMed](#)
57. Oldrini B, *et al.* 2018. *Nat Commun.* 9:1466. [PubMed](#)
58. Xiong X *et al.* 2019. *Mol Cell.* 75(3):644-660. [PubMed](#)
59. She L, *et al.* 2019. *J Immunol.* 203:2520. [PubMed](#)
60. Zhu Y, *et al.* 2021. *EMBO J.* 40:e105320. [PubMed](#)
61. Sefik E, *et al.* 2021. *Nat Biotechnol.* . [PubMed](#)
62. Wells KL, *et al.* 2020. *Elife.* 9:. [PubMed](#)
63. Voss M, *et al.* 2015. *Am J Physiol Lung Cell Mol Physiol.* 309: L188 - L195. [PubMed](#)
64. Choi EW, *et al.* 2020. *Sci Rep.* 10:12001. [PubMed](#)
65. Rangaraju S, *et al.* 2018. *Mol Neurodegener.* 13:24. [PubMed](#)
66. Bogie JFJ, *et al.* 2021. *J Autoimmun.* 124:102723. [PubMed](#)
67. Kovacs M, *et al.* 2021. *Acta Neuropathol Commun.* 9:136. [PubMed](#)
68. Lü X, *et al.* 2021. *Exp Ther Med.* 22:1005. [PubMed](#)
69. Wang X, *et al.* 2020. *Nat Commun.* 4.505555556. [PubMed](#)
70. Peñaloza HF, *et al.* 2018. *Biochem Biophys Rep.* 13:12. [PubMed](#)
71. Chulpanova DS, *et al.* 2021. *Biology (Basel).* 10:. [PubMed](#)
72. Taddio MF, *et al.* 2021. *Mol Imaging Biol.* 23:196. [PubMed](#)
73. Blanchard L, *et al.* 2022. *STAR Protoc.* 3:101444. [PubMed](#)

74. Woods S, *et al.* 2015. *Am J Physiol Lung Cell Mol Physiol.* 308:912. [PubMed](#)
75. Baomei Wang *et al.* 2019. *Cell reports.* 26(6):1614-1626 . [PubMed](#)
76. Zhang S, *et al.* 2022. *Nat Commun.* 13:4744. [PubMed](#)
77. Li X, *et al.* 2021. *Cell Death Dis.* 12:314. [PubMed](#)
78. Gorina R, *et al.* 2014. *J Immunol.* 192:324. [PubMed](#)
79. Kerkhofs D, *et al.* 2020. *Theranostics.* 7.022222222. [PubMed](#)
80. Yamamuro T, *et al.* 2020. *Nat Commun.* 3.340277778. [PubMed](#)
81. Gomzikova MO, *et al.* 2020. *Pharmaceutics.* 12:00. [PubMed](#)
82. Enam S, *et al.* 2017. *Biomaterials.* 10.1016/j.biomaterials.2017.07.013. [PubMed](#)
83. Zhao Y, *et al.* 2020. *Immunity.* 51(6):1059-1073.e9.. [PubMed](#)
84. Doni A, *et al.* 2021. *Nat Commun.* 12:3739. [PubMed](#)
85. Cartwright ANR, *et al.* 2021. *Cancer Immunol Res.* 9:470. [PubMed](#)
86. Yamasaki R, *et al.* 2014. *J Exp Med.* 211:1533. [PubMed](#)
87. Wong L, *et al.* 2013. *J Biol Chem.* 288:35170. [PubMed](#)
88. Yin X, *et al.* 2015. *J Immunol.* 194:4029. [PubMed](#)
89. SL C, *et al.* 2016. *JCI Insight.* 1: 83116. [PubMed](#)
90. Cao Z, *et al.* 2021. *Molecular Cell.* 81(17):3604-3622.e10. [PubMed](#)
91. Westrich JA, *et al.* 2019. *Oncogene.* 38:7166. [PubMed](#)
92. Liu Q, *et al.* 2021. *Adv Mater.* 33:e2102852. [PubMed](#)
93. Sears SM, *et al.* 2022. *Kidney360.* 3:818. [PubMed](#)
94. Zukauskas A, *et al.* 2018. *mSphere.* 3:e00303. [PubMed](#)
95. Bai C, *et al.* 2022. *Exp Ther Med.* 24:673. [PubMed](#)
96. Jaeger N, *et al.* 2020. *Cell Rep.* 33:108331. [PubMed](#)
97. Chen R, *et al.* 2019. *Mol Med Rep.* 1.172916667. [PubMed](#)
98. Akhand SS, *et al.* 2020. *Cancer Immunol Res.* 8:1542. [PubMed](#)
99. Wang X, *et al.* 2021. *Sci Transl Med.* 13:. [PubMed](#)
100. Buschor S, *et al.* 2017. *PLoS Pathogens.* 13(6):e1006476. [PubMed](#)
101. Chuang LT, *et al.* 2021. *Molecules.* 26:. [PubMed](#)

**RRID** [AB\\_893343](#) (BioLegend Cat. No. 103129)  
[AB\\_893339](#) (BioLegend Cat. No. 103130)

## Antigen Details

---

<b>Structure</b>	Protein tyrosine phosphatase (PTP) family, 180-240 kD
<b>Distribution</b>	All hematopoietic cells except mature erythrocytes and platelets
<b>Function</b>	Phosphatase, T and B cell activation
<b>Ligand/Receptor</b>	Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
<b>Cell Type</b>	B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
<b>Biology Area</b>	Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
<b>Molecular Family</b>	CD Molecules
<b>Antigen References</b>	<ol style="list-style-type: none"> <li>1. Barclay A, <i>et al.</i> 1997. <i>The Leukocyte Antigen FactsBook</i> Academic Press.</li> <li>2. Trowbridge IS, <i>et al.</i> 1993. <i>Annu. Rev. Immunol.</i> 12:85.</li> <li>3. Kishihara K, <i>et al.</i> 1993. <i>Cell</i> 74:143.</li> <li>4. Pulido R, <i>et al.</i> 1988. <i>J. Immunol.</i> 140:3851.</li> </ol>
<b>Gene ID</b>	<a href="#">19264</a>

## Related Protocols

---

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats


---

APC anti-mouse CD45, Biotin anti-mouse CD45, FITC anti-mouse CD45, PE anti-mouse CD45, PE/Cyanine5 anti-mouse CD45, Purified anti-mouse CD45, PE/Cyanine7 anti-mouse CD45, APC/Cyanine7 anti-mouse CD45, Alexa Fluor® 488 anti-mouse CD45, Alexa Fluor® 647 anti-mouse CD45, Pacific Blue™ anti-mouse CD45, Alexa Fluor® 700 anti-mouse CD45, PerCP/Cyanine5.5 anti-mouse CD45, PerCP anti-mouse CD45, Alexa Fluor® 594 anti-mouse CD45, Brilliant Violet 421™ anti-mouse CD45, Brilliant Violet 570™ anti-mouse CD45, Brilliant Violet 510™ anti-mouse CD45, Brilliant Violet 605™ anti-mouse CD45, Purified anti-mouse CD45 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse CD45, Brilliant Violet 711™ anti-mouse CD45, Brilliant Violet 785™ anti-mouse

CD45, Brilliant Violet 650™ anti-mouse CD45, APC/Fire™ 750 anti-mouse CD45, Brilliant Violet 750™ anti-mouse CD45, TotalSeq™-A0096 anti-mouse CD45, TotalSeq™-B0096 anti-mouse CD45, Ultra-LEAF™ Purified anti-mouse CD45, Spark Blue™ 550 anti-mouse CD45, Spark NIR™ 685 anti-mouse CD45, TotalSeq™-C0096 anti-mouse CD45, Spark YG™ 570 anti-mouse CD45, PE/Fire™ 640 anti-mouse CD45, APC/Fire™ 810 anti-mouse CD45, PE/Fire™ 700 anti-mouse CD45, Spark Violet™ 538 anti-mouse CD45, Spark YG™ 593 anti-mouse CD45, Spark Blue™ 574 anti-mouse CD45 Antibody

## Product Data

---



C57BL/6 mouse splenocytes stained with 30-F11 PerCP

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587